Current Molecular Pharmacology (CMP) is a prominent journal in the field of cell and molecular pharmacology. Published by Far Publishing, CMP is dedicated to publishing the latest advancements in this area. The journal covers a wide range of topics, including the mechanisms of new drugs, innovative pharmacological technologies, and the application of genomics, proteomics, and metabolomics in drug action. CMP has an impact factor of 2.9 and a CiteScore of 5.5, ranking Q2 in the discipline of pharmacology and pharmacy. It is also indexed in multiple international databases such as SCIE, Google Scholar, PubMed, BIOSIS Previews, EMBASE, Scopus, and MEDLINE. The journal is led by Editor-in-Chief David A. Gewirtz, a professor at Virginia Commonwealth University School of Medicine. He has made significant contributions to the study of anti-tumor drug mechanisms, with an h-index of 61. His research focuses on tumor cell growth arrest and recurrence, autophagy and drug resistance, and the toxicity of tumor drugs. CMP welcomes submissions on various topics, including new drug mechanisms, innovative pharmacological technologies, and the application of omics in pharmacology. For more information, visit the journal's website or submit your manuscript through the provided links: https://www.keaipublishing.com/en/journals/current-molecular-pharmacology/.
News Release